Major clinical trials of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and RAAS inhibitors in patients with diabetes, diabetic cardiomyopathy, and COVID-19: Cardiovascular and metabolic outcomes. The gene discussed is SLC5A2; the disease is diabetic cardiomyopathy.